At the time of writing, Climb Bio Inc [CLYM] stock is trading at $1.35, up 7.14%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CLYM shares have gain 13.45% over the last week, with a monthly amount drifted -2.88%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Climb Bio Inc [NASDAQ: CLYM] stock has seen the most recent analyst activity on June 06, 2025, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $10. Previously, BTIG Research started tracking the stock with Buy rating on May 22, 2025, and set its price target to $7. On December 02, 2024, Leerink Partners initiated with a Outperform rating and assigned a price target of $10 on the stock.
For the past year, the stock price of Climb Bio Inc fluctuated between $1.05 and $9.21. Climb Bio Inc [NASDAQ: CLYM] shares were valued at $1.35 at the most recent close of the market.
Analyzing the CLYM fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.46, Equity is -0.44 and Total Capital is -0.53. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.2767 points at the first support level, and at 1.2033 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.3967, and for the 2nd resistance point, it is at 1.4433.
Ratios To Look Out For
It is important to note that Climb Bio Inc [NASDAQ:CLYM] has a current ratio of 14.25. Also, the Quick Ratio is 14.25, while the Cash Ratio stands at 4.12.
Transactions by insiders
Recent insider trading involved Brennan Aoife, President and CEO, that happened on Jun 30 ’25 when 20618.0 shares were sold. SVP, Finance & CAO, Pimblett Emily completed a deal on Jun 20 ’25 to sell 1242.0 shares. Meanwhile, SVP, Finance & CAO Pimblett Emily sold 1199.0 shares on Mar 20 ’25.
